Literature DB >> 21654650

Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Ken Garber.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21654650     DOI: 10.1038/nbt0611-467

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  24 in total

1.  Incyte comes of age with JAK inhibitor approval.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

2.  Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway.

Authors:  Guanglei Zhuang; Xiumin Wu; Zhaoshi Jiang; Ian Kasman; Jenny Yao; Yinghui Guan; Jason Oeh; Zora Modrusan; Carlos Bais; Deepak Sampath; Napoleone Ferrara
Journal:  EMBO J       Date:  2012-07-06       Impact factor: 11.598

3.  Newsmaker: Lycera.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

4.  Psoriasis: from bed to bench and back.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-07-11       Impact factor: 54.908

5.  What's fueling the biotech engine-2011 to 2012.

Authors:  Saurabh Rob Aggarwal
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

6.  Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908

7.  [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

Authors:  K W Frommer; M Geyer; G S Firestein
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

8.  Tofacitinib.

Authors:  Dennis J Cada; Kendra Demaris; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2013-05

9.  Targeted kinase selectivity from kinase profiling data.

Authors:  Francesca Milletti; Johannes C Hermann
Journal:  ACS Med Chem Lett       Date:  2012-03-14       Impact factor: 4.345

10.  Caerulomycin A enhances transforming growth factor-β (TGF-β)-Smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs).

Authors:  Rama Krishna Gurram; Weshely Kujur; Sudeep K Maurya; Javed N Agrewala
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.